📊 COCP Key Takeaways
Is Cocrystal Pharma, Inc. (COCP) a Good Investment?
Cocrystal Pharma faces severe financial distress with a debt-to-equity ratio of 12.13x and long-term debt of $49.9M against total assets of just $7.4M, creating an unsustainable capital structure. The company is burning cash operationally (-$2.3M FCF) with collapsing revenue (down 69% YoY to just $225K), leaving approximately 2 years of runway at current burn rates despite a modest cash position of $4.7M. Even for an early-stage pharma developer, the leverage and negative operating cash flow create existential solvency risk regardless of R&D pipeline potential.
Cocrystal Pharma's fundamentals are weak: revenue fell sharply, margins are deeply negative, and the business continues to consume cash with no evidence of operating leverage. While liquidity appears adequate in the near term due to a solid cash balance and high current ratio, the combination of persistent losses, negative free cash flow, and very high reported leverage materially weakens financial quality.
Cocrystal Pharma, Inc. Key Strengths (COCP)
- Current ratio of 2.66x indicates short-term liquidity is adequate to meet immediate obligations
- Net loss improving 49.5% YoY suggests operational discipline or one-time charges from prior year
- Cash position of $4.7M provides near-term runway to fund operations and debt service
- Strong near-term liquidity with $7.73M in cash and a 5.78x current ratio
- Asset-light operating profile with minimal capital expenditure requirements
- Positive gross profit indicates some non-zero revenue base despite low scale
COCP Stock Risks: Cocrystal Pharma, Inc. Investment Risks
- Debt-to-equity ratio of 12.13x is critically unsustainable; long-term debt ($49.9M) is 6.7x total assets
- Revenue collapsed 69.3% YoY to minimal $225K, indicating failed commercialization or delayed milestone achievement
- Negative operating cash flow of -$2.3M is unsustainable; company will face refinancing or restructuring risk within 24-36 months at current burn rate
- Equity cushion deteriorating with accumulated losses; negative ROE (-55.9%) and ROA (-31%) indicate value destruction
- Revenue declined 69.3% year over year, indicating poor growth quality and weak commercial traction
- Operating loss of $6.54M and negative free cash flow of $6.47M suggest ongoing cash burn without profitability visibility
- Reported long-term debt of $49.94M and debt/equity of 6.51x imply severe balance-sheet risk, especially given the small equity base
Key Metrics to Watch
- Cash burn rate and remaining runway relative to debt maturity schedules
- Revenue trajectory and success of any clinical trial results or product launches
- Debt refinancing capacity and any covenant violations or restructuring announcements
- Quarterly revenue trend and durability of collaboration or licensing income
- Cash runway, operating cash burn, and any clarification of debt versus total liabilities
Cocrystal Pharma, Inc. (COCP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.66x current ratio provides a solid financial cushion.
COCP Profit Margin, ROE & Profitability Analysis
COCP vs Healthcare Sector: How Cocrystal Pharma, Inc. Compares
How Cocrystal Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cocrystal Pharma, Inc. Stock Overvalued? COCP Valuation Analysis 2026
Based on fundamental analysis, Cocrystal Pharma, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cocrystal Pharma, Inc. Balance Sheet: COCP Debt, Cash & Liquidity
COCP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cocrystal Pharma, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
COCP Revenue Growth, EPS Growth & YoY Performance
COCP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $225.0K | -$2.3M | $-0.17 |
| Q3 2021 | $489.0K | -$2.0M | N/A |
| Q2 2021 | $554.0K | -$2.0M | N/A |
| Q1 2021 | $461.0K | -$2.0M | $-0.04 |
| Q3 2020 | $489.0K | -$324.0K | N/A |
| Q2 2020 | $554.0K | $1.5M | $0.05 |
| Q1 2020 | $461.0K | -$2.0M | $-0.05 |
| Q3 2019 | $492.0K | -$324.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cocrystal Pharma, Inc. Dividends, Buybacks & Capital Allocation
COCP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cocrystal Pharma, Inc. (CIK: 0001412486)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COCP
What is the AI rating for COCP?
Cocrystal Pharma, Inc. (COCP) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COCP's key strengths?
Claude: Current ratio of 2.66x indicates short-term liquidity is adequate to meet immediate obligations. Net loss improving 49.5% YoY suggests operational discipline or one-time charges from prior year. ChatGPT: Strong near-term liquidity with $7.73M in cash and a 5.78x current ratio. Asset-light operating profile with minimal capital expenditure requirements.
What are the risks of investing in COCP?
Claude: Debt-to-equity ratio of 12.13x is critically unsustainable; long-term debt ($49.9M) is 6.7x total assets. Revenue collapsed 69.3% YoY to minimal $225K, indicating failed commercialization or delayed milestone achievement. ChatGPT: Revenue declined 69.3% year over year, indicating poor growth quality and weak commercial traction. Operating loss of $6.54M and negative free cash flow of $6.47M suggest ongoing cash burn without profitability visibility.
What is COCP's revenue and growth?
Cocrystal Pharma, Inc. reported revenue of $225.0K.
Does COCP pay dividends?
Cocrystal Pharma, Inc. does not currently pay dividends.
Where can I find COCP SEC filings?
Official SEC filings for Cocrystal Pharma, Inc. (CIK: 0001412486) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COCP's EPS?
Cocrystal Pharma, Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is COCP's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cocrystal Pharma, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is COCP stock overvalued or undervalued?
Valuation metrics for COCP: ROE of -55.9% (sector avg: 15%), net margin of -1,021.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is COCP's AI grade for 2026?
Our dual AI analysis gives Cocrystal Pharma, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COCP's free cash flow?
Cocrystal Pharma, Inc.'s operating cash flow is $-2.3M, with capital expenditures of $12.0K. FCF margin is -1,045.3%.
How does COCP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,021.8% (avg: 12%), ROE -55.9% (avg: 15%), current ratio 2.66 (avg: 2).
Is Cocrystal Pharma, Inc. carrying too much debt?
COCP has a debt-to-equity ratio of 12.13x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.66 suggests adequate short-term liquidity.